Recent Updates
Recently added Catalysts

EPO906 epothilone B

Phase 2

Carcinoid | Small molecule | Oncology |Novartis AG|Last Updated: Mar 1, 2017

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment33
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00050349EPO906 in Carcinoid and Other Neuroendocrine TumorsPHASE2 COMPLETED 33 — — Jul 1, 2002Apr 1, 2007Mar 1, 20175 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST)
every 12 weeks
Secondary Endpoints
Time to progression
until documented disease progression, death or date of follow up
Overall survival
after treatment, every 3 months (maximum of 12 months)
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
EPO906EXPERIMENTAL -
Interventions
NameTypeDescription
EPO906 epothilone BDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites5

Inclusion Criteria: * Patients with biopsy-proven metastatic carcinoid tumors or other neuroendocrine tumors (Islet cell, Gastrinomas and VIPomas) with at least one measurable lesion (other than bone) that has either not been previously irradiated or if previously irradiated has demonstrated progre...

Countries:United States
Unlock Eligibility Criteria